Limits...
Fibulin-4 is associated with tumor progression and a poor prognosis in ovarian carcinomas.

Chen J, Liu Z, Fang S, Fang R, Liu X, Zhao Y, Li X, Huang L, Zhang J - BMC Cancer (2015)

Bottom Line: Fibulin-4 expression was upregulated in ovarian carcinoma, and positively correlated with MVD and VEGF expression.The serum levels of fibulin-4, CA-125 and CA19-9 in patients with ovarian carcinoma were much higher than those with benign ovarian tumors and normal controls.Compared to CA-125 and CA19-9, fibulin-4 had better diagnostic sensitivity and specificity.

View Article: PubMed Central - PubMed

Affiliation: Department of Maternal and Child Health Care, School of Public Health, Shandong University, Jinan, 250012, China. 77chenjie@sdu.edu.cn.

ABSTRACT

Background: Fibulin-4, a member of the fibulin family of extracellular glycoproteins, is implicated in the progressions of some cancers. However, no information has been available to date regarding the function of fibulin-4 in ovarian carcinoma progression.

Methods: In this study, fibulin-4 mRNA and protein expression in normal ovarian tissue, ovarian tumor, high invasive subclones and low invasive subclones were evaluated by immunohistochemistry and real time reverse transcriptase-polymerase chain reaction (RT-PCR). The serum levels of fibulin-4, cancer antigen 125 (CA-125) and cerbohydrate antigen 199 (CA19-9) in patients with ovarian tumor were measured by enzyme-linked immunosorbent assay and electrochemiluminescent immunoassay. To assess the angiogenic properties of fibulin-4, vascular endothelial growth factor (VEGF) expression and tumor microvessel density were analyzed in ovarian carcinoma by immunohistochemistry.

Results: Fibulin-4 expression was upregulated in ovarian carcinoma, and positively correlated with MVD and VEGF expression. Fibulin-4 overexpression was significantly associated with advanced stage, low differentiation, lymph node metastasis and poor prognosis in patients with ovarian cancer. The serum levels of fibulin-4, CA-125 and CA19-9 in patients with ovarian carcinoma were much higher than those with benign ovarian tumors and normal controls. Compared to CA-125 and CA19-9, fibulin-4 had better diagnostic sensitivity and specificity.

Conclusions: Fibulin-4 is a novel gene that is found overexpressed in ovarian cancer and associated with poor prognostic clinicopathologic features. This study shows that fibulin-4 may serve as a new prognostic factor and as a potential therapeutic target for patients with ovarian cancer in the future.

Show MeSH

Related in: MedlinePlus

Immunohistochemical staining of VEGF and CD34 for MVD. Immunohistochemical staining of VEGF in low differentiation of ovarian carcinoma (A), and high differentiation of ovarian carcinoma (B). (Magnification × 200). Immunohistochemical staining of CD34 for MVD in low differentiation of ovarian carcinoma (C), and high differentiation of ovarian carcinoma (D). (Magnification × 200).
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4359517&req=5

Fig5: Immunohistochemical staining of VEGF and CD34 for MVD. Immunohistochemical staining of VEGF in low differentiation of ovarian carcinoma (A), and high differentiation of ovarian carcinoma (B). (Magnification × 200). Immunohistochemical staining of CD34 for MVD in low differentiation of ovarian carcinoma (C), and high differentiation of ovarian carcinoma (D). (Magnification × 200).

Mentions: Figure 5 shows the representative immunohistochemical staining images of VEGF and CD34. The immunohistochemical expressions of VEGF and fibulin-4 were evaluated with software Imag Pro Plus 6.0 to detect the photodensity. In brief, five positive fields in a section were selected at random and then read using Imag Pro Plus 6.0, finally the average densities were calculated. Pearson correlation tests of MVD (Figure 6A, P < 0.01) and VEGF expression (Figure 6B, P < 0.01) versus fibulin-4 revealed strong positive correlations.Figure 5


Fibulin-4 is associated with tumor progression and a poor prognosis in ovarian carcinomas.

Chen J, Liu Z, Fang S, Fang R, Liu X, Zhao Y, Li X, Huang L, Zhang J - BMC Cancer (2015)

Immunohistochemical staining of VEGF and CD34 for MVD. Immunohistochemical staining of VEGF in low differentiation of ovarian carcinoma (A), and high differentiation of ovarian carcinoma (B). (Magnification × 200). Immunohistochemical staining of CD34 for MVD in low differentiation of ovarian carcinoma (C), and high differentiation of ovarian carcinoma (D). (Magnification × 200).
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4359517&req=5

Fig5: Immunohistochemical staining of VEGF and CD34 for MVD. Immunohistochemical staining of VEGF in low differentiation of ovarian carcinoma (A), and high differentiation of ovarian carcinoma (B). (Magnification × 200). Immunohistochemical staining of CD34 for MVD in low differentiation of ovarian carcinoma (C), and high differentiation of ovarian carcinoma (D). (Magnification × 200).
Mentions: Figure 5 shows the representative immunohistochemical staining images of VEGF and CD34. The immunohistochemical expressions of VEGF and fibulin-4 were evaluated with software Imag Pro Plus 6.0 to detect the photodensity. In brief, five positive fields in a section were selected at random and then read using Imag Pro Plus 6.0, finally the average densities were calculated. Pearson correlation tests of MVD (Figure 6A, P < 0.01) and VEGF expression (Figure 6B, P < 0.01) versus fibulin-4 revealed strong positive correlations.Figure 5

Bottom Line: Fibulin-4 expression was upregulated in ovarian carcinoma, and positively correlated with MVD and VEGF expression.The serum levels of fibulin-4, CA-125 and CA19-9 in patients with ovarian carcinoma were much higher than those with benign ovarian tumors and normal controls.Compared to CA-125 and CA19-9, fibulin-4 had better diagnostic sensitivity and specificity.

View Article: PubMed Central - PubMed

Affiliation: Department of Maternal and Child Health Care, School of Public Health, Shandong University, Jinan, 250012, China. 77chenjie@sdu.edu.cn.

ABSTRACT

Background: Fibulin-4, a member of the fibulin family of extracellular glycoproteins, is implicated in the progressions of some cancers. However, no information has been available to date regarding the function of fibulin-4 in ovarian carcinoma progression.

Methods: In this study, fibulin-4 mRNA and protein expression in normal ovarian tissue, ovarian tumor, high invasive subclones and low invasive subclones were evaluated by immunohistochemistry and real time reverse transcriptase-polymerase chain reaction (RT-PCR). The serum levels of fibulin-4, cancer antigen 125 (CA-125) and cerbohydrate antigen 199 (CA19-9) in patients with ovarian tumor were measured by enzyme-linked immunosorbent assay and electrochemiluminescent immunoassay. To assess the angiogenic properties of fibulin-4, vascular endothelial growth factor (VEGF) expression and tumor microvessel density were analyzed in ovarian carcinoma by immunohistochemistry.

Results: Fibulin-4 expression was upregulated in ovarian carcinoma, and positively correlated with MVD and VEGF expression. Fibulin-4 overexpression was significantly associated with advanced stage, low differentiation, lymph node metastasis and poor prognosis in patients with ovarian cancer. The serum levels of fibulin-4, CA-125 and CA19-9 in patients with ovarian carcinoma were much higher than those with benign ovarian tumors and normal controls. Compared to CA-125 and CA19-9, fibulin-4 had better diagnostic sensitivity and specificity.

Conclusions: Fibulin-4 is a novel gene that is found overexpressed in ovarian cancer and associated with poor prognostic clinicopathologic features. This study shows that fibulin-4 may serve as a new prognostic factor and as a potential therapeutic target for patients with ovarian cancer in the future.

Show MeSH
Related in: MedlinePlus